Time-Limited Venetoclax-Based Combos Improve PFS Outcomes in Treatment-Naïve CLL
June 11th 2022Time-limited targeted therapy with venetoclax plus obinutuzumab with or without ibrutinib demonstrated superior progression-free survival outcomes compared with standard chemoimmunotherapy in patients with chronic lymphocytic leukemia.
Quizartinib Plus Chemo Significantly Improves OS Vs Chemo Alone in Newly Diagnosed FLT3-ITD+ AML
The addition of quizartinib to standard induction and consolidation chemotherapy and then continued as a single agent doubled median overall survival vs standard chemotherapy alone in patients with newly diagnosed FLT3-ITD–positive acute myeloid leukemia.
PRO Results Show Zanubrutinib Improves HRQOL Vs Ibrutinib in R/R CLL/SLL
Patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic leukemia assigned to zanubrutinib reported better health-related quality of life than those administered ibrutinib.
Epcoritamab Plus GemOX Exhibits Promising Early Efficacy in R/R DLCBL
Epcoritamab in combination with gemcitabine plus oxaliplatin displayed encouraging responses with no new safety signals among patients with relapsed/refractory diffuse large B-cell lymphoma who are ineligible for autologous stem cell transplant, according to initial results from the phase 1b/2 EPCORE NHL-2 trial.
Epcoritamab Plus R-DHAX/C Demonstrates High Response Rates and Manageable Safety in DLBCL
June 10th 2022Epcoritamab plus rituximab, dexamethasone, cytarabine, and oxaliplatin or carboplatin displayed encouraging responses in patients with relapsed/refractory diffuse large B-cell lymphoma who are eligible for autologous stem cell transplant, according to preliminary results from arm 4 of the phase 1b/2 EPCORE NHL-2 trial.
NPM1 Mutations, MRD Responses Linked to Long-Term Survival Benefits With Azacitidine in AML
Oral azacitidine was associated with improved long-term survival in patients with acute myeloid leukemia who harbored NPM1 mutations, had intermediate-risk cytogenetics at diagnosis, had a longer treatment duration, or a minimal residual disease response during treatment.
Sintilimab Plus Decitabine Demonstrates 62% ORR in Untreated, Higher-Risk MDS
June 10th 2022The combination of the PD-1 antibody sintilimab and decitabine elicited potent clinical activity and manageable safety with no grade 4 or 5 treatment-related adverse effects as frontline therapy in patients with higher-risk myelodysplastic syndrome, according to preliminary results from a phase 2 trial.
Axi-Cel Induces Superior Responses, Survival in Relapsed/Refractory Follicular Lymphoma
June 12th 2021Compared to currently available therapies, treatment with axicabtagene ciloleucel induced substantial objective response rate, progression-free survival, time to next treatment and overall survival improvements in patients with relapsed/refractory follicular lymphoma.
Naratuximab Emtansine/Rituximab Combo Elicits Clinical Activity in Relapsed/Refractory DLBCL
The combination of naratuximab emtansine and rituximab yielded deep responses, and a duration of response that was not reached in patients with relapsed or refractory diffuse large B-cell lymphoma.
Daratumumab Plus Standard of Care Continues to Improve Survival in Newly Diagnosed Multiple Myeloma
June 12th 2021The addition of daratumumab to lenalidomide and dexamethasone continued to reduced the risk of death by 32% compared with Rd alone in patients with newly diagnosed multiple myeloma who are transplant ineligible after almost 5 years of follow-up.
Frontline Ibrutinib/Venetoclax Yields Superior Outcomes Vs Chlorambucil/Obinutuzumab in CLL
June 12th 2021Fixed-duration ibrutinib and venetoclax as a first-line treatment yielded superior progression-free survival compared with chlorambucil plus obinutuzumab in patients with chronic lymphocytic leukemia.
Rusfertide Eliminates Need for Phlebotomy, Reverses Iron Deficiency in Polycythemia Vera
Rusfertide has been shown to be an effective option for patients with polycythemia vera in that it reverses iron deficiency, improves disease-related symptoms, and eliminates the need for therapeutic phlebotomy.
Real-World Data Highlight Utility of Axi-Cel/Tisa-Cel in DLBCL
June 12th 2021In the first few years of their availability in the United States, axicabtagene ciloleucel and tisagenlecleucel have been used to mostly treat patients with diffuse large b-cell lymphoma in the outpatient setting who are receiving the CAR T-cell therapies prior to failure on 2 prior lines of therapy.
Hillmen Highlights Acalabrutinib’s Tolerability Vs Ibrutinib in Previously Treated CLL
June 12th 2021The next-generation, selective BTK inhibitor acalabrutinib demonstrated noninferiority to ibrutinib in terms of progression-free survival in patients with previously treated chronic lymphocytic leukemia in the phase 3 ELEVATE-RR trial.
Lenalidomide/Rituximab Continues to Improve PFS in iNHL, MCL
June 11th 2021The combination of lenalidomide and rituximab continued to improve progression-free survival with durable outcomes and a manageable safety profile in patients with indolent B-cell non-Hodgkin lymphomas and mantle cell lymphomas.